World Vaccine Congress Lyon - Terrapinn's 11th Annual Congress.
The 11th Annual World Vaccine Congress, held in Lyon, included topics covering new therapeutic developments in the field of vaccines. This conference report highlights selected presentations on the role of big pharma in vaccine development, the future direction of vaccine R&D, influenza preparedness in Europe, and vaccines for Staphylococcus aureus, CMV and cancer. Investigational drugs discussed include an H5N1 influenza vaccine program from Baxter International Inc/DynPort Vaccine Co LLC, FP-01 (Immune Targeting Systems Ltd), FluGEM (Mucosis BV), a nonstructural protein-1-altered live-attenuated influenza vaccine candidate from Vivaldi Biosciences Inc, PentaStaph (GlaxoSmithKline plc) and StaphVAX (Nabi Biopharmaceuticals), VCL-CB01 (Vical Inc) and astuprotimut-r (GlaxoSmithKline).
Sovran
Liza
L
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. liza.sovran@thomsonreuters.com
D000818:Animals; D015195:Drug Design; D004345:Drug Industry / Q000639:trends; D015507:Drugs, Investigational / Q000494:pharmacology*; D006801:Humans; D007252:Influenza Vaccines / Q000276:immunology / Q000627:therapeutic use; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control; D014612:Vaccines / Q000276:immunology* / Q000627:therapeutic use
D015507:Drugs, Investigational; D007252:Influenza Vaccines; D014612:Vaccines